Skip to main content

Cepesedan (Canada)

This page contains information on Cepesedan for veterinary use.
The information provided typically includes the following:
  • Cepesedan Indications
  • Warnings and cautions for Cepesedan
  • Direction and dosage information for Cepesedan

Cepesedan

This treatment applies to the following species:
Company: Modern Veterinary Therapeutics

(Detomidine hydrochloride injection - 10 mg/mL)

DIN 02335441

Injectable sedative and analgesic for use in horses only - Sterile Solution.

For veterinary use only.

Active Ingredient - Each mL contains:

Detomidine hydrochloride

10 mg

Non-medicinal ingredients - Each mL contains:

Methylparahydroxybenzoate (preservative)

1 mg

Sodium chloride

5.9 mg

Water for injection

q.s.

Description

CEPESEDAN™ is a synthetic alpha-2 adrenoceptor agonist with sedative and analgesic properties. The chemical name is 1H-imidazole, 4-[(2,3-dimethylphenyl)methyl]-, hydrochloride and the active ingredient‘s name is detomidine hydrochloride. It is a white, crystalline, water soluble substance having a molecular weight of 222.7. The molecular formula is C12H14N2•HCl.

Chemical Structure:

Cepesedan Indications

CEPESEDAN™ is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.

Dosage and Administration

Administer CEPESEDAN™ intravenously or intramuscularly at the rates of 20 or 40 µg detomidine hydrochloride per kg of body weight (0.2 to 0.4 mL of CEPESEDAN™ per 100 kg or 220 lbs.), depending upon the depth and duration of sedation and analgesia required. Analgesia is more pronounced when the drug is given intravenously. Sedative and analgesic effects will usually occur in 2 to 5 minutes and will persist for 30 minutes to 2 hours, depending upon the dosage and route of administration.

Prior to and following injection, the animal should be allowed to rest quietly. The full effect should be reached within 2 to 4 minutes after I.V. injection and 3 to 5 minutes after intramuscular injection.

Contra-indications: Not to be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Detomidine hydrochloride should not be used in breeding horses since the potential risk has not been assessed in either stallions or mares.

Cepesedan Caution

The drug is a potent α-2 agonist which should be used with extreme caution with other sedatives, analgesics, or anesthetics as these are likely to produce additive effects. The use of epinephrine should be avoided, except in anesthetic emergency, since epinephrine may potentiate the effects of α-2 agonists. Careful consideration should be given prior to the administration of CEPESEDAN™ to horses in endotoxic or traumatic shock or approaching shock, to horses with advanced liver or kidney disease or other pre-existing conditions of stress such as extreme heat or cold, high altitude, or fatigue. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur. Protect treated horses from temperature extremes. Food and water should be withheld until the sedative effect of CEPESEDAN™ has worn off.

Warning

This drug is not to be administered to horses that are to be slaughtered for use in food. Keep out of reach of children.

Adverse Reactions

As with all α2-agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation) exists. There has been an occasional appearance of arrhythmia, hypertension, and bradycardia in horses treated with detomidine hydrochloride. Piloerection, sweating and salivation, and, occasionally, slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Decreased heart rate and respiratory rate may occur. Incoordination or staggering is usually seen only during the first 3 to 5 minutes after injection, until animals have secured a firm footing. Because of continued lowering of the head during sedation, passive congestion may occur occasionally in the lips, the facial area, and the upper airways. Tying the head in a slightly elevated position generally prevents these effects.

NOTE TO USERS: Animals should not be left unattended during the development and duration of sedation. Allowing the horse to stand quietly for 5 minutes prior to and after injection may improve the response to CEPESEDAN™. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers.

Overdosage: Detomidine hydrochloride is tolerated in horses at up to 200 µg per kg of body weight (10 times the low dosage and five times the high dosage). In safety studies in horses, detomidine hydrochloride at 400 µg per kg body weight, administered once a day for 3 consecutive days produced microscopic foci of myocardial necrosis in 1 of 8 horses.

Clinical Pharmacology

CEPESEDAN™, a non-narcotic sedative and analgesic, is a potent α-2 adrenoceptor agonist which produces sedation and superficial and visceral analgesia which is dose dependent in its depth and duration. Profound lethargy and a characteristic lowering of the head with reduced sensitivity to environmental stimuli (sounds, etc.) are seen with detomidine. A short period of incoordination is characteristically followed by immobility and a firm stance with front legs well spread. The analgesic effect is most readily seen as an increase in the pain threshold at the body surface. With intravenous administration, both superficial and visceral analgesia are seen to depths which allow for such procedures as flank incision after local anesthesia, penetration of the peritoneum, and rectal examinations for diagnosis of colic. Sensitivity to touch is little affected and in some cases may actually be enhanced.

Chemical restraint and pain relief provided by α-2 adrenoceptor agonists facilitates the handling of fractious animals, and aids in the conduct of uncomfortable diagnostic or therapeutic procedures such as endoscopy, nasogastric tubing, and rectal examinations. It also facilitates surgical procedures (with or without local anesthesia) such as suturing of skin lacerations, flank incisions for ovariectomy, vaginal suturing, and castration. With detomidine administration, heart rate is markedly decreased, blood pressure is initially elevated and then a steady decline to normal is seen. A transient change in the conductivity of the cardiac muscle may occur, as evidenced by partial atrioventricular (AV) and sinoauricular (SA) blocks. This change in the conductivity of the cardiac muscle may be prevented by I.V. administration of atropine at a dosage of 0.02 mg/kg of body weight. A diuretic effect is usually observed within 45 to 60 minutes after treatment. Effects on blood clotting time or other hematological parameters was not encountered at dosages of 20 or 40 µg per kg of body weight. Respiratory responses include an initial slowing of respiration within a few seconds to 1 to 2 minutes after administration, increasing to normal within 5 minutes. An initial decrease in tidal volume is followed by an increase.

Post-approval experience: Although all adverse reactions are not reported, the following information is based on voluntary post-approval drug experience reporting. It is generally recognized that this results in under-reporting. The adverse events here reflect reported observations regardless of association with causality. Adverse events are listed by body system, in descending order of frequency:

Systemic disorders: Lethargy, hyperthermia

Neurological disorders: Ataxia, sedation and muscular tremors, loss of consciousness

Respiratory tract disorders: Tachypnea, dyspnea

Cardiovascular disorders: Tachycardia

Immune system disorders: Urticaria

Digestive tract disorders: Abdominal pain

Skin and appendages disorders: Hyperhidrosis

Storage

15°-30°C (59°-86°F) - Protect from light. Content should be used within 90 days of the first puncture (20 punctures maximum).

Presentation: Supplied in 5mL and 20mL multidose vials containing 10mg detomidine hydrochloride per mL.

Manufactured for: Modern Veterinary Therapeutics, LLC, Miami, Florida 33186 - USA

Tel. (888) 590 9839

Fax +1 305 503 8585

info@modernveterinarytherapeutics.com

www.modernveterinarytherapeutics.com

Orders & Product information: Call 1 888 590 9839

Revision Date: 5 March 2021

CPN: 1354002.7

MODERN VETERINARY THERAPEUTICS, LLC
14343 SW 119TH AVE., MIAMI, FL, 33186
Telephone:   407-852-8039
Toll-Free:   888-590-9839
Fax:   305-503-8585
Website:   www.modernveterinarytherapeutics.com
Email:   info@modernveterinarytherapeutics.com
Every effort has been made to ensure the accuracy of the Cepesedan information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2021 Animalytix LLC. Updated: 2021-10-04